Merck & Company, Inc. (MRK)

Merck (MRK) shares rose nearly 4% in early trade on Friday after the company said a European medicines committee issued a positive opinion for its Keytruda (pembrolizumab) and Padcev (enfortumab vedotin) combination.

Merck has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6.8%. The stock now trades at $113.99, marking a 20% gain. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Taken together, the convergence of a landmark Phase 3 NSCLC readout for sac-TMT, a fresh EU regulatory recommendation for a Keytruda combination in bladder cancer, and a solid Q1 earnings beat with raised guidance has given investors multiple reasons to re-rate the stock higher today.

• Merck's Q1 2026 earnings beat expectations, revenue guidance raised. Merck & Co Inc (MRK) opened up by 4.50%. The Pharmaceuticals & Medical Research sector is up by 0.44%. The company outperformed the industry. Top 3 stocks by turnover in the sector: Akari Therapeutics PLC (AKTX) up 100.49%; ...

On May 22, 2026, Kelun-Biotech announced significant findings from its studies on a novel ADC, sacituzumab tirumotecan, which targets TROP2. When combined with